Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models
- Correspondence to Dr Jonathan E Grim, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mailstop D2-100, Seattle, WA 98109, USA;
- Received 4 June 2013
- Revised 2 August 2013
- Accepted 6 August 2013
- Published Online First 2 September 2013
The recent explosion in cancer genomics provides an unprecedented view of the genetic changes present in solid tumours. The characterisation of colorectal cancer samples via DNA sequencing has confirmed the importance of established oncogene and tumour suppressor pathways (including the ‘mountains’ of Apc, Tp53 and Ras) but has also identified novel cancer genes that are mutated in a small percentage of patient samples (hills).1 ,2 Furthermore, these studies give a new appreciation of the spectrum of gene mutations present in cancers, especially in candidate tumour suppressor genes (TSGs). While classic genetics teaches that two hits are required to inactivate TSGs, sequencing studies show that heterozygous mutations are also quite frequent. Some of these are loss of function alleles, while others are recurrent missense mutations known as ‘hotspots’. Now, researchers are charged with the task of understanding how these genetic changes contribute to cancer development, invasion and spread.
Why are heterozygous mutations in TSGs commonly found in cancer genomes? While many of these are passenger mutations, some single allele mutations can significantly alter tumour suppressor protein expression or function. This, in turn, leads to incremental changes in growth or to other hallmarks of cancer. The concept of haploinsufficiency refers to such situations where decreased dosage of certain gene products is sufficient to promote tumorigenesis.3 However, the impact of most heterozygous mutations is largely unknown, because they …